Bios Capital Management, LP In8 Bio, Inc. Transaction History
Bios Capital Management, LP
- $79.2 Billion
- Q1 2025
A detailed history of Bios Capital Management, LP transactions in In8 Bio, Inc. stock. As of the latest transaction made, Bios Capital Management, LP holds 8,600,001 shares of INAB stock, worth $19.9 Million. This represents 1.8% of its overall portfolio holdings.
Number of Shares
8,600,001
Previous 8,600,001
-0.0%
Holding current value
$19.9 Million
Previous $2.21 Billion
35.46%
% of portfolio
1.8%
Previous 2.35%
Shares
1 transactions
Others Institutions Holding INAB
# of Institutions
18Shares Held
16.8MCall Options Held
0Put Options Held
0-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$4.8 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL93.4KShares$215,8000.0% of portfolio
-
State Street Corp Boston, MA88.7KShares$205,0030.0% of portfolio
-
Xtx Topco LTD London, X069.7KShares$161,0250.0% of portfolio
-
Black Rock Inc. New York, NY57.1KShares$131,8540.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $56.6M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...